Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T35445
|
||||
| Former ID |
TTDR00819
|
||||
| Target Name |
Mothers against decapentaplegic homolog 3
|
||||
| Gene Name |
SMAD3
|
||||
| Synonyms |
HMAD-3; HSMAD3; JV15-2; MMad3; Mad3; Mothers against DPP homolog 3; SMAD 3; Smad3; TGF-beta response effector Smad3; SMAD3
|
||||
| Target Type |
Successful
|
||||
| Disease | Ocular disease [ICD10: H00-H59] | ||||
| Function |
Transcriptional modulator activated by tgf-beta (transforming growth factor) and activin type 1 receptor kinase. Smad3 is a receptor-regulated smad (r-smad). In mouse required for establishemnt of the mucosal immune response.
|
||||
| Target Validation |
T35445
|
||||
| UniProt ID | |||||
| Sequence |
MSSILPFTPPIVKRLLGWKKGEQNGQEEKWCEKAVKSLVKKLKKTGQLDELEKAITTQNV
NTKCITIPRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELRAMELCEFAFNMKKDEV CVNPYHYQRVETPVLPPVLVPRHTEIPAEFPPLDDYSHSIPENTNFPAGIEPQSNIPETP PPGYLSEDGETSDHQMNHSMDAGSPNLSPNPMSPAHNNLDLQPVTYCEPAFWCSISYYEL NQRVGETFHASQPSMTVDGFTDPSNSERFCLGLLSNVNRNAAVELTRRHIGRGVRLYYIG GEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGF EAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSIR CSSVS |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | FLUORESCEIN | Drug Info | Approved | Ocular disease | [1] |
| Inhibitor | ELLAGIC ACID | Drug Info | [2] | ||
| FLUORESCEIN | Drug Info | [2] | |||
| GNF-PF-2272 | Drug Info | [2] | |||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.